Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 4:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 839 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Coagulation Disorder, Blood Clear all
Completed Phase 1 Interventional

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

NCT00104923
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
fenretinide
Drug
Lead sponsor
California Cancer Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Jun 10, 2026, 4:34 PM EDT
Completed Early Phase 1 Interventional

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

NCT00424242
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Pemetrexed
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Jun 10, 2026, 4:34 PM EDT
Completed Phase 4 Interventional

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

NCT00002386
View directory record Official record
Conditions
HIV Infections, Hemophilia A
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 4:34 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

NCT07008118
View directory record Official record
Conditions
Myeloproliferative Neoplasms
Interventions
INCA035784
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Phoenix, Arizona • Palo Alto, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jun 10, 2026, 4:34 PM EDT
Terminated Phase 3 Interventional Results available

Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A

NCT01405742
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
rF.VIII
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Jun 10, 2026, 4:34 PM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

NCT01410227
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Recombinant von Willebrand factor (rVWF), Placebo, Recombinant factor VIIII (rFVIII)
Biological · Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
10
States / cities
Sacramento, California • Miami, Florida • Peoria, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jun 10, 2026, 4:34 PM EDT
Withdrawn Phase 1 Interventional

The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

NCT06291415
View directory record Official record
Conditions
Immune Thrombocytopenia, Blood Platelet Disorder, Hematologic Diseases, Purpura, Thrombocytopenic, Purpura, Blood Coagulation Disorder, Thrombotic Microangiopathies, Hemorrhagic Disorders, Autoimmune Diseases, Immune System Diseases, Hemorrhage, Pathologic Processes, Skin Manifestations, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic, Primary Immune Thrombocytopenia, ITP - Immune Thrombocytopenia
Interventions
HMPL-523
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Irvine, California • Georgetown, Delaware • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jun 10, 2026, 4:34 PM EDT
Withdrawn Phase 3 Interventional

Emicizumab PUPs and Nuwiq ITI Study

NCT04030052
View directory record Official record
Conditions
Hemophilia A
Interventions
Nuwiq (low dose protocol), HEMLIBRA, Nuwiq (Atlanta protocol)
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jun 10, 2026, 4:34 PM EDT
Completed Not applicable Interventional

The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs

NCT00212459
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
Counseling, Control
Behavioral
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
12 Years to 20 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Jun 10, 2026, 4:34 PM EDT
Completed Early Phase 1 Interventional

Factor IX as Adjunctive Therapy to Emicizumab (EMIX)

NCT05281718
View directory record Official record
Conditions
Hemophilia A
Interventions
Factor IX
Drug
Lead sponsor
Tulane University
Other
Eligibility
12 Years to 120 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Metairie, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Jun 10, 2026, 4:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding

NCT05711524
View directory record Official record
Conditions
Hypofibrinogenemia, Bleeding
Interventions
Traditional Cryoprecipitate, Pathogen-Reduced Cryoprecipitate
Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jun 10, 2026, 4:34 PM EDT
Withdrawn Phase 2 Interventional

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

NCT00514982
View directory record Official record
Conditions
Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
Interventions
Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 4:34 PM EDT
Recruiting Phase 4 Interventional

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

NCT05936580
View directory record Official record
Conditions
Hemophilia A
Interventions
Nuwiq
Drug
Lead sponsor
Octapharma
Industry
Eligibility
12 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jun 10, 2026, 4:34 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

NCT04596995
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Jun 10, 2026, 4:34 PM EDT
Active, not recruiting No phase listed Observational

A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

NCT04158934
View directory record Official record
Conditions
Hemophilia A
Interventions
ADYNOVI/ADYNOVATE
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Not listed
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jun 10, 2026, 4:34 PM EDT
Terminated No phase listed Observational

Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

NCT04904276
View directory record Official record
Conditions
ITP, Immune Thrombocytopenia
Interventions
Fostamatinib
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Tamarac, Florida • Springfield, Illinois • Kansas City, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Jun 10, 2026, 4:34 PM EDT
Completed No phase listed Observational

Journey of Patients With Vasculitis From First Symptom to Diagnosis

NCT03410290
View directory record Official record
Conditions
Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatous Vasculitis, Temporal Arteritis, Giant Cell Arteritis, Granulomatosis With Polyangiitis, Wegener Granulomatosis, Henoch Schonlein Purpura, IgA Vasculitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Urticarial Vasculitis
Interventions
Online Questionnaire
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Jun 10, 2026, 4:34 PM EDT
Completed Phase 3 Interventional Results available

BAX 855 Pediatric Study

NCT02210091
View directory record Official record
Conditions
Hemophilia A
Interventions
Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, PEGylated Recombinant Factor VIII
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 11 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Phoenix, Arizona • Denver, Colorado • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Jun 10, 2026, 4:34 PM EDT
Completed Phase 2 Interventional Results available

Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim

NCT01143038
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Romiplostim
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Anaheim, California • Orange, California • Boynton Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Jun 10, 2026, 4:34 PM EDT
Recruiting No phase listed Observational

VCRC Tissue Repository

NCT02967068
View directory record Official record
Conditions
Aortitis, Cutaneous Vasculitis, Eosinophilic Granulomatosis With Polyangiitis, Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Henoch-Schonlein Purpura, IgA Vasculitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Churg-Strauss Syndrome
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
6
States / cities
Boston, Massachusetts • Cleveland, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jun 10, 2026, 4:34 PM EDT
Completed No phase listed Observational

Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A

NCT02971930
View directory record Official record
Conditions
Hemophilia A
Interventions
BAY94-9027
Biological
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Jun 10, 2026, 4:34 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B

NCT00076557
View directory record Official record
Conditions
Hemophilia B
Interventions
Adeno-Associated Viral with Human Factor IX
Genetic
Lead sponsor
Avigen
Industry
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Palo Alto, California • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2007 · Synced Jun 10, 2026, 4:34 PM EDT
Completed Phase 2 Interventional

Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation

NCT00621894
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
LGD-4665, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Manchester, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Jun 10, 2026, 4:34 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT03862157
View directory record Official record
Conditions
Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Eosinophilic Leukemia, Not Otherwise Specified, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid Neoplasm, Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Unclassifiable, Overt Primary Myelofibrosis, Polycythemia Vera, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Prefibrotic/Early Primary Myelofibrosis
Interventions
Azacitidine, Pevonedistat, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jun 10, 2026, 4:34 PM EDT